EQT Life Science develops medications, devices, and methods to combat it.
Business Model:
Revenue: $42.9M
Employees: 11-50
EQT life science was acquired by
EQT.
The acquisition happend on 2021-11-10.
Details of the transaction were not public
Address: Johannes Vermeerplein 9
City: Amsterdam
State: noord-holland
Zip: 1071 DV
Country: NL
EQT life science develops innovative medicines, devices and tools to address the single most important thing that matters to all the preservation of health. The organization believes that such opportunities add value to all stakeholders.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
1/2016 | Rainier Therapeutics | Series A | 13M |
8/2021 | Cardior Pharmaceuticals | Series B | 0 |
1/2010 | Kreatech Diagnostics | Series B | 0 |
4/2020 | Kiadis Pharma | Post-IPO Equity | 5.5M |
6/2011 | Mendor | Series B | 11.7M |
9/2016 | Immunic Therapeutics | Series A | 19.6M |
1/2016 | ViCentra | Series B | 10.9M |
9/2014 | Affimed | Series E | 0 |
11/2011 | Harvest Automation | Series B | 7.9M |
2/2010 | Promethera Biosciences | Series A | 7.3M |
5/2020 | Arvelle Therapeutics | Series A | 0 |
8/2007 | FlowCardia | Series C | 0 |
8/2007 | Isto Technologies | Series E | 0 |
11/2003 | Affectis Pharmaceuticals | Series A | - |
1/2023 | Amolyt Pharma | Series C | 0 |
4/2000 | NewBiotics | Venture Round | 6.3M |
9/2021 | Amolyt Pharma | Series B | 0 |
10/2015 | Luxendo | Series A | 0 |
5/2011 | Cobalt Technologies | Series D | 0 |
5/2019 | DNA Script | Series B | 38.5M |
8/2018 | Artios Pharma | Series B | 0 |
1/2011 | Nexstim | Venture Round | 0 |
6/2009 | Pronota | Series B | 7.4M |
9/2019 | Pharvaris | Series B | 66M |
1/2009 | BMEYE | Series A | - |
3/2014 | Hybrigenics | Post-IPO Equity | 8.4M |
7/2020 | Cybin | Series B | 0 |
6/2022 | ImCheck Therapeutics | Series C | 0 |
4/2004 | NewBiotics | Series E | 4.6M |
12/2007 | Vivendy Therapeutics | Series A | 15.4M |
5/2016 | Nouscom | Series A | 13.6M |
11/2017 | Xeltis | Series C | 53M |
5/2008 | Asoyia | Venture Round | 4M |
2/2022 | Perfuze | Series A | 0 |
7/2021 | Artios Pharma | Series C | 0 |
12/2006 | BMEYE | Series A | - |
12/2021 | ViCentra | Series C | 0 |
3/2010 | Seahorse Bioscience | Series D | 5M |
10/2015 | Sequana Medical | Series C | 0 |
8/2021 | Visus Therapeutics | Equity | 20M |
6/2020 | OneProjects | Series A | 12.4M |
1/2010 | Harvest Automation | Series A | 4M |
4/2014 | Heart Metabolics | Series A | 20M |
1/2007 | 4-Antibody AG | Series A | 18.4M |
10/2012 | Cobalt Technologies | Venture Round | 5M |
3/2019 | SNIPR Biome | Series A | 50M |
12/2014 | Xeltis | Series B | 33.5M |
4/2005 | DNage | Series A | 1.9M |
1/2016 | Pharvaris | Series A | 16.3M |
4/2006 | Pronota | Series A | 7.8M |
1/2010 | Merus | Series B | 0 |
4/2012 | Cobalt Technologies | Venture Round | 2.9M |
1/2005 | OctoPlus | Series B | 23.9M |
5/2018 | Rainier Therapeutics | Series B | 20M |
2/2007 | Prosensa | Series A | 18M |
9/2010 | Harvest Automation | Series A | 1.3M |
10/2013 | Harvest Automation | Series C | 11.8M |
5/2003 | Santarus | Series D | 51.4M |
7/2017 | Simplify Medical | Series B | 21M |
2/2018 | Simplify Medical | Series B | 23M |
3/2007 | Okairos | Series A | 9.6M |
11/2009 | Kreatech Diagnostics | Venture Round | 0 |
10/2007 | Hyperion Therapeutics | Debt Financing | 15M |
9/2007 | Nexstim | Venture Round | 10.9M |
4/2016 | Onward | Series A | 29.5M |
10/1999 | Devgen | Series B | 24.7M |
1/2012 | Pronota | Series C | 4.8M |
1/2007 | Movetis | Series A | 63.8M |
2/2010 | arGEN-X | Series A | 4.5M |
2/2009 | ActoGeniX | Private Equity Round | 17.4M |
2/2007 | ActoGeniX | Venture Round | 26.1M |
7/2019 | AM Pharma | Series F | 130.1M |
1/2019 | INNOVO by Atlantic Therapeutics | Series B | 32.1M |
11/2012 | Kiadis Pharma | Venture Round | 0 |
7/2001 | NewBiotics | Series C | 0 |
9/2016 | Vivasure Medical | Series C | 18.3M |
9/2017 | Immunic Therapeutics | Series A | 11.9M |
2/2006 | EyeSense AG | Series A | 0 |
2/2023 | Xeltis | Series D | 0 |
7/2020 | DNA Script | Series B | 50M |
8/2022 | eTheRNA immunotherapies | Series B | 0 |
6/2022 | Ariceum Therapeutics | Series A | 0 |
7/2002 | Scion Pharmaceuticals | Series B | 0 |
7/2003 | PamGene | Series B | 11.3M |
8/2006 | Pronota | Series A | 10.6M |
5/2021 | Binx Health | Series E | 0 |
7/2019 | Amolyt Pharma | Series A | 0 |
4/2007 | Affimed | Series B | 32M |
6/2011 | Sapiens Steering Brain Stimulation | Series A | 18.7M |
11/2009 | Vivoryon Therapeutics | Series B | 0 |
1/2012 | Vivoryon Therapeutics | Venture Round | 19.4M |
8/2015 | Kuros Biosciences | Post-IPO Equity | 15.3M |
11/2014 | Curetis | Series B | 0 |
10/2021 | DNA Script | Series C | 0 |
8/2007 | BioProcessors | Series C | 10M |
12/2018 | XyloCor Therapeutics | Series A | 17M |
10/2012 | Affimed | Series D | 20.1M |
8/2016 | Rotation Medical | Series B | 12M |
7/2014 | Rotation Medical | Series B | 27.2M |
1/2021 | Neurent Medical | Series B | 0 |
7/2009 | Pasteuria Bioscience | Series B | 0 |
6/2015 | Neuravi | Series B | 21.5M |
12/2009 | Curetis | Series A | 27.9M |
2/2019 | Arvelle Therapeutics | Series A | 0 |
12/2000 | PamGene | Series A | 6.2M |
3/2021 | XyloCor Therapeutics | Series A | 0 |
1/2012 | Prosensa | Venture Round | 0 |
10/2007 | Syntaxin | Series B | 32M |
10/2021 | OneProjects | Series A | 8M |
5/2023 | VarmX | Series B | 0 |
6/2007 | Kiadis Pharma | Venture Round | 0 |
12/2021 | AviadoBio | Series A | 0 |
2/2018 | Merus | Post-IPO Equity | 55.8M |
7/2021 | Xilis | Series A | 0 |
9/2019 | Nkarta Therapeutics | Series B | 114M |
7/2020 | ViCentra | Venture Round | 0 |
1/2017 | Binx Health | Series D | 0 |
3/2023 | QurAlis | Series B | 0 |
12/2015 | Xeltis | Series B | 3.3M |
7/2011 | Binx Health | Series B | 27.1M |
10/2013 | Merus | Series B | 42.2M |
11/2009 | Trinity Biosystems | Debt Financing | 7.5M |
9/2012 | IlluminOss Medical | Series C | 0 |
8/2021 | T-knife | Series B | 110M |
3/2015 | Cardiac Dimensions | Equity | 15.2M |
9/2018 | Endotronix | Series D | 0 |
9/2020 | Cardiac Dimensions | Series C | 17.5M |
10/2021 | Egle Therapeutics | Series A | 0 |
10/2008 | Cobalt Technologies | Series C | 0 |
4/2015 | Merus | Series C | 79.1M |
8/2016 | Mint Solutions | Series B | 5.6M |
5/2017 | ImCheck Therapeutics | Series A | 21.9M |
5/2017 | Cardior Pharmaceuticals | Series A | 16.3M |
3/2016 | eTheRNA immunotherapies | Series A | 26.6M |
5/2012 | Celladon | Venture Round | 10M |
5/2003 | BioXell | Series B | 19.9M |
7/2020 | Vico Therapeutics | Series A | 31M |
3/2004 | 4-Antibody AG | Seed Round | 2.1M |
7/2014 | Mint Solutions | Series A | 6M |
4/2020 | FoRx Therapeutics | Seed Round | 10.8M |
11/2017 | Orphazyme | Post-IPO Equity | 0 |
4/2023 | Evommune | Series B | 50M |
4/2021 | Onward | Venture Round | 0 |
12/2019 | ImCheck Therapeutics | Series B | 53.2M |
4/2014 | Binx Health | Series B | 0 |
3/2017 | Rainier Therapeutics | Series B | 30M |
7/2020 | VarmX | Series B | 36.3M |
11/2016 | OxThera | Series D | 34.1M |
1/2010 | Cellerix | Series C | 37.7M |
11/2009 | Cellerix | Series B | 40.5M |
9/2007 | Cellerix | Series B | 37.2M |
11/2021 | HotSpot Therapeutics | Series C | 0 |
4/2023 | Evommune | Series B | 0 |
3/2023 | QurAlis | Series B | 0 |
2/2023 | Xeltis | Series D | 0 |
1/2023 | Amolyt Pharma | Series C | 0 |
8/2022 | eTheRNA immunotherapies | Series B | 0 |
6/2022 | ImCheck Therapeutics | Series C | 0 |
6/2022 | Ariceum Therapeutics | Series A | 0 |
2/2022 | Perfuze | Series A | 0 |
12/2021 | ViCentra | Series C | 0 |
12/2021 | AviadoBio | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|